MAP4K4 and amyotrophic lateral sclerosis: We then validated the fidelity of this approach to identify neuroprotective drugs by reproducing the ability of several pharmacological MAP4K4 inhibitors, originally identified by our group, to rescue this ALS MN toxicity.